Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research
Zacks Research has upgraded Viking Therapeutics (NASDAQ:VKTX) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a target price of $96.62. The company's stock rose 7.8% on Tuesday after exceeding quarterly loss expectations. Despite recent insider stock sales totaling $6.27 million to cover tax obligations, institutional investors hold a significant 76.03% stake in Viking Therapeutics.
Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In
Viking Therapeutics (VKTX) stock appears expensive despite a significant 463.7% return over five years. The company fails most valuation checks, with its Price-to-Book ratio of 9.5x being double its peers, suggesting that investors are already paying a high price for anticipated pipeline success. Future clinical and commercial progress will need to be rapid and clear to justify the current premium valuation.
Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX
Timothy G. Youngquist 2020 Irrevocable Trust significantly increased its stake in Viking Therapeutics (VKTX) by 141.6% in the second quarter, now holding 271,849 shares valued at $10.61 million. Institutional ownership of VKTX remains high at 76.03%, with several major firms also increasing their holdings. Despite insider sales by the COO and CFO to cover tax obligations, analysts maintain a "Moderate Buy" rating with an average price target of $96.62, and the company reported a smaller-than-expected quarterly loss.
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Eli Lilly (LLY) and Novo Nordisk (NVO) dominated the GLP-1 market in May, but Truist initiated coverage on Viking Therapeutics (VKTX) with a "Buy" rating and a 162% upside target, calling it a "differentiated player." Truist highlighted Viking's VK2735 candidate and its dual oral-plus-injectable strategy as key advantages in the competitive obesity market. While LLY and NVO saw significant gains, smaller players like Viking lagged, but the new analyst coverage aims to put VKTX back on investors' radar.
Viking Therapeutics, Inc. Revenue Breakdown – NASDAQ:VKTX
The article provides a title for Viking Therapeutics, Inc. Revenue Breakdown (NASDAQ:VKTX) and indicates that it is a financial page on TradingView. However, the content primarily consists of navigation links, disclaimers, and website feature lists rather than actual revenue breakdown data. It mentions market data and reference data providers but does not display any specific financial figures.
Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX
Cornerstone Capital Inc. has acquired a new stake of 85,470 shares in Viking Therapeutics (NASDAQ:VKTX) worth approximately $3.33 million during the second quarter, representing 0.07% of the company. Institutional investors collectively own 76.03% of VKTX, and the stock maintains a "Moderate Buy" consensus rating from analysts with an average target price of $96.62. Despite recent price objective reductions from some firms, Viking Therapeutics reported a quarterly loss of $1.10 per share, outperforming analyst estimates.
(VKTX) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Viking Therapeutics Inc. (NASDAQ: VKTX) price dynamics, highlighting a neutral near-term sentiment that could moderate mid-term weakness. It identifies a mid-channel oscillation pattern and an exceptional short setup with a 50.5:1 risk-reward ratio. The analysis also details institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
VKTX Maintained by JP Morgan -- Price Target Lowered to $65
JP Morgan has maintained an "Overweight" rating for Viking Therapeutics (VKTX) but lowered its price target from $75 to $65, reflecting cautious optimism amid challenges in the biotechnology sector. The company has a GF Score™ of 34/100, indicating below-average performance in key financial metrics, particularly profitability, and has seen significant insider selling. Investors should consider these factors as VKTX is in a clinical stage with negative cash flow, making traditional valuation metrics difficult to apply.
Viking Therapeutics (VKTX) Is Up 5.6% After Expanding At-The-Market Offerings And Shelf Registration - Has The Bull Case Changed?
Viking Therapeutics (VKTX) recently expanded its financing options by filing a $500 million at-the-market follow-on offering and an omnibus shelf registration, following a Q2 2026 net loss of US$128.02 million and previous fundraising of US$159.59 million. This move aims to provide balance sheet flexibility to fund its VK2735 obesity franchise trials and broader pipeline as losses increase. While the clinical story for VK2735 remains compelling, investors should be aware of the ongoing risk of incremental equity issuance and potential future dilution tied to these financing activities.
J.P. Morgan Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $65
J.P. Morgan has reiterated its Buy rating for Viking Therapeutics (VKTX.US) but has revised its target price downwards to $65. This adjustment reflects an updated outlook on the company's valuation while still recommending the stock to investors.
Viking Therapeutics (VKTX) Raises Fresh Capital After Wider Losses, Is It Still Undervalued?
Viking Therapeutics (VKTX) recently reported wider Q2 losses and increased its funding flexibility through new equity offerings. Despite a recent 21% share price drop, the company has strong long-term returns. Analysts question if its current valuation, which pegs fair value at $92.72 (64.1% undervalued), justifies the increased risk, especially given its high Price-to-Book ratio of 9.5x while remaining unprofitable.
Viking Therapeutics (VKTX) Raises Fresh Capital After Wider Losses, Is It Still Undervalued?
Viking Therapeutics (VKTX) recently reported wider second-quarter losses and raised fresh capital through equity offerings. Despite a short-term share price drop, the company has seen strong longer-term returns, prompting investors to reassess its valuation. Simply Wall St indicates that VKTX is 64.1% undervalued with a fair value of $92.72, though this is dependent on successful trial outcomes and ongoing funding.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Viking Therapeutics (NASDAQ:VKTX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $97.88, significantly higher than its current share price. Despite recent insider stock sales by the CFO and CEO to cover tax obligations, institutional investors maintain strong support, owning 76.03% of the company. The biopharmaceutical company also reported a narrower-than-expected quarterly loss, beating analyst estimates.
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History
This article provides a comprehensive overview of Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company. It includes real-time stock price data, historical performance charts, key financial metrics, and details on its drug candidates in clinical trials for metabolic and endocrine disorders. The article also presents analyst recommendations and comparative data with similar biotechnology companies.
Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?
Viking Therapeutics recently reported a wider Q2 net loss and expanded its funding options through a universal shelf registration and a $500 million at-the-market stock offering. While these moves provide capital to advance its obesity drug candidate VK2735 through trials, they also highlight the company's reliance on external funding and the potential for dilution for existing shareholders. The investment narrative hinges on the successful progression of VK2735 and its commercial potential, with analysts offering varied perspectives on the impact of the new financing tools.
Does Viking’s Expanded Shelf and ATM Funding Shift the Bull Case For Viking Therapeutics (VKTX)?
Viking Therapeutics recently reported a wider Q2 net loss and filed for a universal shelf registration and a $500 million at-the-market stock offering to expand funding options. This move aims to support the long-term development of its weight-loss and metabolic disorder pipeline, particularly the VK2735 obesity drug candidate, as the company is currently revenue-less and dependent on external capital. While these financing tools offer flexibility for advancing clinical trials, they also introduce risks of dilution for existing shareholders.
Viking Therapeutics: Why This Clinical-Stage, Licensed-Technology Play Is a Highly Speculative Bet for Equity Investors
Viking Therapeutics is considered a highly speculative investment due to its clinical-stage status, limited operating history, and expected substantial operating losses. The company's reliance on licensed technologies from Ligand Pharmaceuticals and the uncertain prospects of its drug candidates further elevate its risk profile for investors. Despite these risks, Wall Street analysts have issued a "Strong Buy" consensus rating for VKTX stock.
Viking Therapeutics Stock Moves Lower: What's Going On?
Viking Therapeutics (VKTX) shares experienced a decline despite reporting a narrower-than-expected second-quarter loss, primarily due to increased research and development costs for clinical trials. The company's pipeline includes ongoing Phase 3 trials for VK2735 and upcoming data from a maintenance dosing study, with a promising oral formulation also in development. Despite the stock drop, an analyst maintained a "Buy" rating with an increased price objective, signaling continued confidence in the company's future.
This Insider Has Just Sold Shares In Viking Therapeutics
Viking Therapeutics President Brian Lian recently sold US$4.9 million worth of stock, representing 6.3% of his holding. While insiders sold more than they bought over the last year, the company still reports 2.4% insider ownership, which suggests reasonable alignment with shareholders. The article notes some caution regarding the sales history but highlights the company's "flawless balance sheet" and low risk.
Viking Therapeutics (Nasdaq: VKTX) deepens loss as obesity and NASH drugs advance
Viking Therapeutics reported a net loss of $286.3 million for the first half of 2026, widening from $111.2 million a year prior, due to increased R&D spending on its obesity and NASH drug pipeline. Despite the losses, the company maintains strong liquidity with $501.7 million in cash and short-term investments, and has advanced its key drug candidates, including VK2735 for obesity (now in Phase 3 injectable and Phase 2 oral studies) and VK2809 for NASH (showing positive 52-week histology). The company also authorized a new $500 million share repurchase program and terminated its prior ATM agreement, establishing a new one.
Earnings call transcript: Viking Therapeutics posts Q2 2026 loss beat
Viking Therapeutics (VKTX) reported a narrower-than-expected loss of $1.10 per share for Q2 2026, surpassing analyst estimates of $1.23, although its net loss widened compared to the previous year due to increased R&D spending. The company is advancing its lead obesity drug candidate, VK2735, in Phase III trials, with both subcutaneous and oral formulations, and is also developing VK3019 for obesity treatment. Viking maintains a strong cash balance of $502 million, expected to fund operations into 2028, and is focused on building its commercial and clinical infrastructure.
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
Viking Therapeutics (VKTX) reported a narrower-than-expected Q2 2026 loss of $1.10 per share, surpassing the Zacks Consensus Estimate of a $1.21 loss, despite a significant 92.4% surge in R&D expenses due to pipeline development, primarily for its lead obesity candidate VK2735. The company is advancing both injectable and oral formulations of VK2735 in phase III studies, with plans to initiate two more oral VK2735 phase III studies in Q4 2026 and expects maintenance study results in Q3 2026. Viking maintains a strong cash position, with $502 million, projected to fund operations into 2028.
Viking Therapeutics Stock Moves Lower: What's Going On?
Viking Therapeutics (NASDAQ: VKTX) stock decreased by 4.49% despite reporting a narrower-than-expected net loss of $1.10 per share for the quarter ending June 30. This loss was primarily due to increased R&D costs which nearly doubled. The company maintains a strong cash position and has upcoming pipeline milestones, including data from a maintenance dosing study for weight loss and continued progress for its oral formulation of VK2735.
Viking Therapeutics Advances VK2735 Oral Program Into Phase 3 Trials
Viking Therapeutics is moving its oral tablet formulation of VK2735 into Phase 3 trials in Q4 2026, building on its strong cash position of $502 million and two fully enrolled Phase 3 subcutaneous trials. The company aims for VK2735 to be the first oral dual GLP-1/GIP agonist on the market, following the FDA's approval of an oral semaglutide for obesity in December 2025. Additionally, Viking expects top-line data from a maintenance dosing study of VK2735 by the end of Q3 2026 and initiated a Phase 1 study for VK3019, an amylin receptor agonist, for pipeline diversification.
Viking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline ...
Viking Therapeutics reported a significant net loss increase in Q2 2026 due to higher R&D expenses, yet remains optimistic about its obesity pipeline. The company highlighted progress in its VK2735 Phase III program, with upcoming oral trials, and the entry of VK3019 into Phase I development. Despite increased cash burn, Viking maintains a strong cash balance to fund key milestones.
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking Therapeutics (VKTX) stock has underperformed its GLP-1 peers in July, but CEO Brian Lian believes its obesity drug VK2735 could offer a competitive edge through multiple treatment options, including weekly injection, daily pill, and potentially less-frequent dosing for maintenance. The company's lead drug showed up to 15% weight loss in Phase 2 trials, and Viking is also developing VK3019, an amylin-targeting drug, which could further boost efficacy. Oral VK2735 Phase 3 studies are expected to begin in Q4, with the potential to be the first oral dual GLP-1 agonist on the market.
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness
Insiders at Viking Therapeutics recently sold shares worth US$15 million, with the average selling price ranging from US$66.00 to US$89.00. This significant insider selling event could suggest that the stock might be overvalued, prompting investors to consider various valuation metrics. Despite the selling, the company's valuation metrics and future growth prospects remain crucial for a comprehensive assessment.
Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29
Viking Therapeutics (NASDAQ:VKTX) stock is under scrutiny for its cash burn ahead of its Q2 earnings report on July 29. Analysts expect increased losses due to surging research and operating expenses, prompting investor focus on cash levels, expenditure, and clinical trial timelines. The company faces stiff competition in the obesity drug market from Eli Lilly and Novo Nordisk, which have advanced their own therapies.
Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT
This article provides financial information for Viking Therapeutics, Inc. (DUS:1VT) on the Düsseldorf Stock Exchange. It focuses on the company's revenue breakdown, including top segments and regional performance, sourced from FactSet and ICE Data Services.
VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620
Viking Therapeutics Inc (VKTX) is a clinical-stage biopharmaceutical company focused on treatments for metabolic and endocrine disorders, with lead programs including VK2735 and VK2809. The company's stock is currently trading at $34.77, down 1.75%, and analysts have a "Buy" rating with an average target price of $93.22. Despite high institutional ownership and significant growth potential, its fundamentals are considered relatively weak, and the stock has shown poor performance recently.
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News
Viking Therapeutics (VKTX) stock has seen significant returns over the past five years, but current valuations suggest it may be overvalued, particularly when considering its price-to-book (P/B) ratio. The high valuation is partly driven by excitement around new diabetes and metabolic therapies, though the company's P/B of 8.2x far exceeds the biotech industry average. Investors are weighing the potential for its pipeline to justify this premium against the risk of overpaying for future growth.
Viking Therapeutics (VKTX.US) will release its earnings report after market close on July 29.
Viking Therapeutics (VKTX.US) is scheduled to release its earnings report after the market closes on July 29. Investors will be observing this announcement for insights into the company's financial performance.
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) stock underperformed the broader market, falling 5.15% in the latest session compared to losses for the S&P 500, Dow, and Nasdaq. The company also underperformed the Medical sector over the past month. Investors are anticipating its upcoming earnings release on July 29, 2026, with an expected EPS significant drop year-over-year and analysts maintaining a "Sell" rating for the stock.
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News
Viking Therapeutics (VKTX) stock has shown strong past performance but appears overvalued based on current metrics. The company's P/B ratio of 8.2x is significantly higher than the broader biotech industry average, driven by excitement around its diabetes and metabolic therapies. Investors need to assess whether the potential for future revenue from its pipeline justifies the current premium or if the valuation is inflated.
Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Grows
Viking Therapeutics (VKTX) has appointed Dorothy Gemmell, a healthcare executive with expertise in commercial execution and digital health, to its Board of Directors. This appointment signals a growing commercial focus for the clinical-stage biopharmaceutical company as it advances its pipeline in obesity and metabolic disorders. Investors will monitor how this governance change influences strategy, partnerships, and launch preparations, especially as the company lacks current revenue but is progressing key drug candidates like VK2735 and VK3019.
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Viking Therapeutics, Inc. has appointed Dorothy Gemmell to its Board of Directors, effective immediately. Ms. Gemmell brings over 25 years of leadership experience in healthcare, digital health, and commercialization, which will be invaluable as Viking advances its therapies and prepares for the potential launch of VK2735. Her expertise in developing commercialization strategies and building high-performing teams is expected to significantly contribute to the company's long-term goals.
Dorothy Gemmell Joins Viking Board After 25+ Years in Healthcare
Viking Therapeutics (NASDAQ: VKTX) has appointed Dorothy Gemmell to its Board of Directors, leveraging her over 25 years of experience in healthcare, digital health, and commercialization. Her expertise is expected to be crucial as Viking advances its metabolic pipeline, particularly in preparation for the potential launch of VK2735. This appointment aims to strengthen the company's commercialization capabilities and translate innovation into market success.
Press Release: Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Viking Therapeutics has announced the appointment of Dorothy Gemmell to its Board of Directors, effective immediately. Gemmell brings extensive experience in commercialization leadership within the biotechnology industry, having held senior roles at companies like Genentech, Amgen, and Onyx Pharmaceuticals. Her expertise is expected to be invaluable as Viking advances its metabolic and endocrinological disease programs.
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Viking Therapeutics, Inc. (NASDAQ: VKTX) has announced it will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide corporate updates. A webcast and telephone replay will also be available for those unable to attend the live call.
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced it will release its second-quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates. A replay of the call will be available until August 5, 2026, and a webcast archive will be accessible on the company's website.
Viking Therapeutics’ Q2 results arrive after markets close
Viking Therapeutics (NASDAQ: VKTX) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide corporate updates. Investors can access the call via phone or live webcast, with replays and an archive available for a limited time afterward.
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free and no-obligation consultation to discuss potential damages and corporate governance reforms. Shareholders are urged to act promptly as there may be limited time to enforce their rights, emphasizing that their participation contributes to the integrity of financial markets.
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Viking Therapeutics, Inc. announced it will release its financial results for the second quarter of 2026 after market close on Wednesday, July 29, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide corporate updates. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders, with lead programs for obesity in Phase 3 clinical studies.
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on pipeline updates, particularly for its lead candidate VK2735 for obesity treatment. The company has no marketed drugs, so no revenues are expected, and analysts forecast a loss of $1.21 per share. VKTX has a history of missing earnings estimates and currently holds a Zacks Rank #4 (Sell), despite its stock outperforming the industry year-to-date.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
Viking Therapeutics (VKTX) stock performed strongly, gaining 1.95% while the broader market indices like the S&P 500, Dow, and Nasdaq fell. The company's stock has risen 19.72% over the past month, outperforming its sector and the S&P 500. Analysts expect Viking Therapeutics to report an EPS of -$1.21 for its upcoming earnings, and the stock currently holds a Zacks Rank of #4 (Sell).
Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial
Viking Therapeutics (VKTX) has initiated a Phase 1 study for VK3019, a potential weight loss therapy. Despite recent stock fluctuations, the company shows strong long-term momentum, with Simply Wall St's analysis suggesting it is 61% undervalued compared to a fair value of $92.72. However, the company faces execution risks due to no current revenue and significant R&D spending, while its P/B ratio indicates it looks expensive on book value.
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on updates regarding its pipeline, particularly the obesity drug VK2735. The company's earnings have consistently missed estimates, and with no marketed drugs, revenue generation is not anticipated. Key areas of interest will include the ongoing maintenance dosing study for VK2735 and plans for the late-stage program of its oral version.
Law firm probes Viking Therapeutics officers for possible self-dealing harming shareholders
Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties through potential self-dealing, which could result in shareholder damages. The firm is encouraging long-term shareholders to contact them for free consultations to protect their rights.
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival
Viking Therapeutics' new obesity drug candidate, VK3019, demonstrated stronger early weight-loss signals in animal studies compared to Novo Nordisk's amylin therapy, although VKTX stock dipped slightly after the announcement. The company plans to begin Phase 1 testing for VK3019 soon and is also advancing its primary candidate, VK2735, into Phase 3 trials for both injectable and oral forms. Despite a Q1 net loss driven by increased R&D spending, Viking maintains a strong cash balance and positive retail investor sentiment.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Viking Therapeutics (VKTX) stock fell 5.54% in the latest trading session, underperforming the broader market which saw gains. Despite this dip, the company's shares have increased significantly over the last month. Investors are anticipating VKTX's upcoming financial results, with expected EPS of -$1.21, and paying close attention to analyst estimate revisions which are currently reflected in its Zacks Rank #4 (Sell) rating.
